Olaparib improves health related quality of life in patients with metastatic castration-resistant prostate cancer.
©Sanford Radom, MD
Treatment with Olaparib was associated with a reduction in pain and improvement in health-related quality of life compared with physician’s choice of hormone therapy (enzalutamide or abiraterone) in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair deficiency genetic mutations called homologous recombination repair (HRR) gene alterations.
The median time to first opiate use for cancer-related pain was significantly longer in the patients treated with Olaparib (18.0 months verses 7.5 months) than in the control group of the study.
The symptomatic and health-related quality of life benefits observed with Olaparib compared with control treatment support the clinical benefit of improved radiographic progression-free survival in men with metastatic castration-resistant prostate cancer and HRR gene alterations who had disease progression after a previous next-generation hormonal drug such as abiraterone acetate or enzalutamide.
Renal & Urology News, Mistry, S. March 28, 2022.
